No Cover Image

Journal article 140 views 78 downloads

A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2

Therese M.-L. Andersson, Mark J. Rutherford, Tor Åge Myklebust, Bjørn Møller, Melina Arnold, Isabelle Soerjomataram, Freddie Bray, Hazem Abd Elkader, Gerda Engholm, Dyfed Huws, Alana Little, Lorraine Shack, Paul M. Walsh, Ryan R. Woods, D.Maxwell Parkin, Paul C. Lambert

Cancer Epidemiology, Volume: 76, Start page: 102085

Swansea University Author: Dyfed Huws

Check full text

DOI (Published version): 10.1016/j.canep.2021.102085

Abstract

Accurately recorded vital status of individuals is essential when estimating cancer patient survival. When deaths are ascertained by linkage with vital statistics registers, some may be missed, and such individuals will wrongly appear to be long-term survivors, and survival will be overestimated. In...

Full description

Published in: Cancer Epidemiology
ISSN: 1877-7821 1877-783X
Published: Elsevier BV 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59120
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-01-10T14:21:21Z
last_indexed 2022-01-19T04:28:57Z
id cronfa59120
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-01-18T17:08:25.4604114</datestamp><bib-version>v2</bib-version><id>59120</id><entry>2022-01-10</entry><title>A way to explore the existence of &#x201C;immortals&#x201D; in cancer registry data &#x2013; An illustration using data from ICBP SURVMARK-2</title><swanseaauthors><author><sid>d4b1f62e65a55f5ad21c5778c6e03af9</sid><firstname>Dyfed</firstname><surname>Huws</surname><name>Dyfed Huws</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-01-10</date><deptcode>FGMHL</deptcode><abstract>Accurately recorded vital status of individuals is essential when estimating cancer patient survival. When deaths are ascertained by linkage with vital statistics registers, some may be missed, and such individuals will wrongly appear to be long-term survivors, and survival will be overestimated. Interval-specific relative survival that levels off above one indicates that the survival among the cancer patients is better than expected, which could be due to the presence of immortals. We included colon cancer cases diagnosed in 1995-1999 within the 19 jurisdictions in seven countries participating in ICBP SURVMARK-2, with follow-up information available until end-2015. Interval-specific relative survival was estimated for each year following diagnosis, by country and age group at diagnosis. The interval-specific relative survival levels off at 1 for all countries and age groups, with two exceptions: for the age group diagnosed at age 75 years and above in Ireland, and, to a lesser extent, in New Zealand. Overall, a subset of immortals are not apparent in the early years within the ICBP SURVMARK-2 study, except for possibly in Ireland. We suggest this approach as one strategy of exploring the existence of immortals, and to be part of routine checks of cancer registry data. [Abstract copyright: Crown Copyright &#xA9; 2021. Published by Elsevier Ltd. All rights reserved.]</abstract><type>Journal Article</type><journal>Cancer Epidemiology</journal><volume>76</volume><journalNumber/><paginationStart>102085</paginationStart><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1877-7821</issnPrint><issnElectronic>1877-783X</issnElectronic><keywords>Cancer registry, Cancer Survival, Immortals</keywords><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-02-01</publishedDate><doi>10.1016/j.canep.2021.102085</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine, Health and Life Science - Faculty</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>FGMHL</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>The ICBP-SurvMArk-2 project and its data collection were supported by the ICBP which is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust.</funders><lastEdited>2022-01-18T17:08:25.4604114</lastEdited><Created>2022-01-10T14:17:39.1541474</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Therese M.-L.</firstname><surname>Andersson</surname><order>1</order></author><author><firstname>Mark J.</firstname><surname>Rutherford</surname><order>2</order></author><author><firstname>Tor &#xC5;ge</firstname><surname>Myklebust</surname><order>3</order></author><author><firstname>Bj&#xF8;rn</firstname><surname>M&#xF8;ller</surname><order>4</order></author><author><firstname>Melina</firstname><surname>Arnold</surname><order>5</order></author><author><firstname>Isabelle</firstname><surname>Soerjomataram</surname><order>6</order></author><author><firstname>Freddie</firstname><surname>Bray</surname><order>7</order></author><author><firstname>Hazem Abd</firstname><surname>Elkader</surname><order>8</order></author><author><firstname>Gerda</firstname><surname>Engholm</surname><order>9</order></author><author><firstname>Dyfed</firstname><surname>Huws</surname><order>10</order></author><author><firstname>Alana</firstname><surname>Little</surname><order>11</order></author><author><firstname>Lorraine</firstname><surname>Shack</surname><order>12</order></author><author><firstname>Paul M.</firstname><surname>Walsh</surname><order>13</order></author><author><firstname>Ryan R.</firstname><surname>Woods</surname><order>14</order></author><author><firstname>D.Maxwell</firstname><surname>Parkin</surname><order>15</order></author><author><firstname>Paul C.</firstname><surname>Lambert</surname><order>16</order></author></authors><documents><document><filename>59120__22089__fb25880f134d41388a98a95b4e572528.pdf</filename><originalFilename>59120.pdf</originalFilename><uploaded>2022-01-10T14:20:05.4526197</uploaded><type>Output</type><contentLength>415366</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article under the CC BY license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-01-18T17:08:25.4604114 v2 59120 2022-01-10 A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2 d4b1f62e65a55f5ad21c5778c6e03af9 Dyfed Huws Dyfed Huws true false 2022-01-10 FGMHL Accurately recorded vital status of individuals is essential when estimating cancer patient survival. When deaths are ascertained by linkage with vital statistics registers, some may be missed, and such individuals will wrongly appear to be long-term survivors, and survival will be overestimated. Interval-specific relative survival that levels off above one indicates that the survival among the cancer patients is better than expected, which could be due to the presence of immortals. We included colon cancer cases diagnosed in 1995-1999 within the 19 jurisdictions in seven countries participating in ICBP SURVMARK-2, with follow-up information available until end-2015. Interval-specific relative survival was estimated for each year following diagnosis, by country and age group at diagnosis. The interval-specific relative survival levels off at 1 for all countries and age groups, with two exceptions: for the age group diagnosed at age 75 years and above in Ireland, and, to a lesser extent, in New Zealand. Overall, a subset of immortals are not apparent in the early years within the ICBP SURVMARK-2 study, except for possibly in Ireland. We suggest this approach as one strategy of exploring the existence of immortals, and to be part of routine checks of cancer registry data. [Abstract copyright: Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.] Journal Article Cancer Epidemiology 76 102085 Elsevier BV 1877-7821 1877-783X Cancer registry, Cancer Survival, Immortals 1 2 2022 2022-02-01 10.1016/j.canep.2021.102085 COLLEGE NANME Medicine, Health and Life Science - Faculty COLLEGE CODE FGMHL Swansea University The ICBP-SurvMArk-2 project and its data collection were supported by the ICBP which is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust. 2022-01-18T17:08:25.4604114 2022-01-10T14:17:39.1541474 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Therese M.-L. Andersson 1 Mark J. Rutherford 2 Tor Åge Myklebust 3 Bjørn Møller 4 Melina Arnold 5 Isabelle Soerjomataram 6 Freddie Bray 7 Hazem Abd Elkader 8 Gerda Engholm 9 Dyfed Huws 10 Alana Little 11 Lorraine Shack 12 Paul M. Walsh 13 Ryan R. Woods 14 D.Maxwell Parkin 15 Paul C. Lambert 16 59120__22089__fb25880f134d41388a98a95b4e572528.pdf 59120.pdf 2022-01-10T14:20:05.4526197 Output 415366 application/pdf Version of Record true This is an open access article under the CC BY license true eng http://creativecommons.org/licenses/by/4.0/
title A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
spellingShingle A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
Dyfed Huws
title_short A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
title_full A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
title_fullStr A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
title_full_unstemmed A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
title_sort A way to explore the existence of “immortals” in cancer registry data – An illustration using data from ICBP SURVMARK-2
author_id_str_mv d4b1f62e65a55f5ad21c5778c6e03af9
author_id_fullname_str_mv d4b1f62e65a55f5ad21c5778c6e03af9_***_Dyfed Huws
author Dyfed Huws
author2 Therese M.-L. Andersson
Mark J. Rutherford
Tor Åge Myklebust
Bjørn Møller
Melina Arnold
Isabelle Soerjomataram
Freddie Bray
Hazem Abd Elkader
Gerda Engholm
Dyfed Huws
Alana Little
Lorraine Shack
Paul M. Walsh
Ryan R. Woods
D.Maxwell Parkin
Paul C. Lambert
format Journal article
container_title Cancer Epidemiology
container_volume 76
container_start_page 102085
publishDate 2022
institution Swansea University
issn 1877-7821
1877-783X
doi_str_mv 10.1016/j.canep.2021.102085
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Accurately recorded vital status of individuals is essential when estimating cancer patient survival. When deaths are ascertained by linkage with vital statistics registers, some may be missed, and such individuals will wrongly appear to be long-term survivors, and survival will be overestimated. Interval-specific relative survival that levels off above one indicates that the survival among the cancer patients is better than expected, which could be due to the presence of immortals. We included colon cancer cases diagnosed in 1995-1999 within the 19 jurisdictions in seven countries participating in ICBP SURVMARK-2, with follow-up information available until end-2015. Interval-specific relative survival was estimated for each year following diagnosis, by country and age group at diagnosis. The interval-specific relative survival levels off at 1 for all countries and age groups, with two exceptions: for the age group diagnosed at age 75 years and above in Ireland, and, to a lesser extent, in New Zealand. Overall, a subset of immortals are not apparent in the early years within the ICBP SURVMARK-2 study, except for possibly in Ireland. We suggest this approach as one strategy of exploring the existence of immortals, and to be part of routine checks of cancer registry data. [Abstract copyright: Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.]
published_date 2022-02-01T04:16:10Z
_version_ 1763754084561584128
score 11.012813

Similar Items